{"entity":{"id":"nct07085169","kind":"trial","name":"Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC","aka":[],"tldr":"A phase 2 trial in colorectal cancer, run by Ruijin Hospital, now recruiting.","summary":"Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC is a phase 2, interventional study registered as NCT07085169 by Ruijin Hospital, with a registry enrolment figure of 50 participants, started 2025-08-01 and due to reach its primary completion in 2027-08-01. Interventions recorded: Trifluridine/tipiracil (TAS-102) plus bevacizumab. Conditions listed: Colo-rectal Cancer; Third-line and Beyond Therapy; TAS 102; Bevacizumab. Primary outcome: 6-month progression-free survival rate. Colorectal eligibility wording from the registry: \"histologically confirmed adenocarcinoma of the colon or rectum\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07085169","url":"https://clinicaltrials.gov/study/NCT07085169"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07085169","phase":"2","setting":"Low-dose Trifluridine/Tipiracil With Bevacizumab in Refractory Metastatic Colorectal Cancer: a Multicenter, Single-arm, Phase 2 Study","sponsor":"Ruijin Hospital","enrolled":50,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07085169/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}